|
|
Volumn 334, Issue 6054, 2011, Pages 298-299
|
|
Vaccine trial meets modest expectations, buoys hopes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MALARIA VACCINE;
VACCINE;
BACTERIAL INFECTION;
CLINICAL EFFECTIVENESS;
DISEASE TRANSMISSION;
DRUG COST;
HUMAN;
IMMUNE RESPONSE;
MALARIA;
MORTALITY;
NOTE;
PRIORITY JOURNAL;
PROTEIN ENGINEERING;
UNSPECIFIED SIDE EFFECT;
VACCINATION;
VIRUS INFECTION;
WORLD HEALTH ORGANIZATION;
DRUG INDUSTRY;
ECONOMICS;
IMMUNIZATION;
INFANT;
MALARIA FALCIPARUM;
PHASE 3 CLINICAL TRIAL (TOPIC);
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
IMMUNIZATION SCHEDULE;
INFANT;
MALARIA VACCINES;
MALARIA, FALCIPARUM;
|
|
EID: 80054831408
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.334.6054.298 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
